Literature DB >> 9873215

Struvite stones.

J S Rodman1.   

Abstract

Struvite stones constitute only about 2-3% of the stones reaching the laboratory for analysis, but the clinical problems they create including sepsis and even renal demise are greater than with any other stone type. This article reviews the evidence that bacterial urease, usually from a Proteus species, is responsible for the chemical changes in urine which result in struvite formation. Available urease inhibitors and other forms of medical management of patients with these stones are discussed. A patient with struvite stones should be assumed to have a progressive disease which cannot be ignored. Even after seemingly successful elimination of stones with lithotripsy and/or percutaneous nephrolithotomy, careful medical follow-up is critical. The medical profession is probably underutilizing postprocedure hemiacidrin irrigation because of shortsighted financial considerations. Primary-care physicians need to be educated in the importance of aggressive management of Proteus and other urea-splitting infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9873215     DOI: 10.1159/000046299

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  14 in total

Review 1.  The history of kidney stone dissolution therapy: 50 years of optimism and frustration with renacidin.

Authors:  Ricardo D Gonzalez; Bryant M Whiting; Benjamin K Canales
Journal:  J Endourol       Date:  2011-10-14       Impact factor: 2.942

Review 2.  [Evidence-based pharmacological metaphylaxis of stone disease].

Authors:  M Straub; R E Hautmann
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

3.  Is it safe to prescribe ascorbic acid for urinary acidification in stone-forming patients with alkaline urine?

Authors:  Yasser A Noureldin; Alexandrine da Silva; Nader Fahmy; Sero Andonian
Journal:  Turk J Urol       Date:  2017-04-18

4.  Proteus bacteriuria is associated with significant morbidity in spinal cord injury.

Authors:  E W Hung; R O Darouiche; B W Trautner
Journal:  Spinal Cord       Date:  2006-12-19       Impact factor: 2.772

Review 5.  Kidney stones: an update on current pharmacological management and future directions.

Authors:  Hongshi Xu; Anna L Zisman; Fredric L Coe; Elaine M Worcester
Journal:  Expert Opin Pharmacother       Date:  2013-03       Impact factor: 3.889

Review 6.  [Urinary tract infections and Urolithiasis].

Authors:  A Meissner; C Mamoulakis; N Laube
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

7.  Rat strains differ in susceptibility to Ureaplasma parvum-induced urinary tract infection and struvite stone formation.

Authors:  Leticia Reyes; Mary Reinhard; L J O'donell; Janet Stevens; Mary B Brown
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

Review 8.  ACP Best Practice No 181: Chemical pathology clinical investigation and management of nephrolithiasis.

Authors:  T M Reynolds
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

Review 9.  Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline.

Authors:  M Straub; W L Strohmaier; W Berg; B Beck; B Hoppe; N Laube; S Lahme; M Schmidt; A Hesse; K U Koehrmann
Journal:  World J Urol       Date:  2005-11-29       Impact factor: 4.226

10.  Struvite Urolithiasis in Long-Evans Rats.

Authors:  Jassia Pang; Tiffany M Borjeson; Nicola M A Parry; James G Fox
Journal:  Comp Med       Date:  2015-12       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.